Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Knowledge of immune mechanisms responsible for the cross-protection between highly divergent viruses such as human immunodeficiency virus type 1 (HIV-1) and HIV-2 may contribute to an understanding of whether virus variability may be overcome in the design of vaccine candidates which are broadly protective across the HIV subtypes. We demonstrate that despite the significant difference in virus amino acid sequence, the majority of HIV-2-infected individuals with different HLA molecules possess a dominant cytotoxic T-cell response which is able to recognize HIV-1 Gag protein. Furthermore, HLA-B5801-positive subjects show broad cross-recognition of HIV-1 subtypes since they mounted a T-cell response that tolerated extensive amino acid substitutions within HLA-B5801-restricted HIV-1 and HIV-2 epitopes. These results suggests that HLA-B5801-positive HIV-2-infected individuals have an enhanced ability to react with HIV-1 that could play a role in cross-protection.


Journal article


Journal of virology

Publication Date





2439 - 2448


Medical Research Council Laboratories, Fajara, The Gambia, West Africa.


Leukocytes, Mononuclear, T-Lymphocytes, Cytotoxic, Cells, Cultured, Humans, HIV-1, HIV-2, HIV Infections, Peptides, Gene Products, nef, Gene Products, gag, Gene Products, pol, HLA-B Antigens, Epitopes, T-Lymphocyte, Cross Reactions, Structure-Activity Relationship, nef Gene Products, Human Immunodeficiency Virus